Oxytocin

Tɛmplet:Infobox drug/title
Names
Pronunciation	/ˌɒksɪˈtoʊsɪn/
Trade names	Pitocin, Syntocinon, others
	IUPAC name 1-({(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-leucylglycinamide;
Clinical data
Main uses	Post partum bleeding, starting labor
Side effects	Excessive contraction of the uterus, nausea, slow heart rate
WHO AWaRe	Script error: No such module "WDfetch".
Pregnancy; category	Tɛmplet:Infobox drug/pregnancy category
Routes of; use	Intranasal, IV, IM
Defined daily dose	15 U (by injection, in the nose); 200 U (by mouth)
External links
AHFS/Drugs.com	Tɛmplet:Drugs.com
Legal
[[Regulation of therapeutic goods \|Tɛmplet:Engvar data]]	Tɛmplet:Infobox drug/licence
Legal status	Tɛmplet:Infobox drug/legal status
Pharmacokinetics
Protein binding	30%
Metabolism	Liver and elsewhere (via oxytocinases)
Elimination half-life	1–6 min (IV); ~2 h (intranasal)
Excretion	Biliary and kidney
Identifiers
CAS Number	Tɛmplet:Infobox drug/formatCASnumber; Tɛmplet:Infobox drug/formatCASnumber;
PubChem CID	Tɛmplet:Infobox drug/formatPubChemCID; Tɛmplet:Infobox drug/formatPubChemCID;
PubChem SID	Tɛmplet:Infobox drug/formatPubChemSID; Tɛmplet:Infobox drug/formatPubChemSID;
IUPHAR/BPS	Tɛmplet:Infobox drug/formatIUPHARBPS; Tɛmplet:Infobox drug/formatIUPHARBPS;
DrugBank	Tɛmplet:Infobox drug/formatDrugBank; Tɛmplet:Infobox drug/formatDrugBank;
ChemSpider	Tɛmplet:Infobox drug/formatChemSpider; Tɛmplet:Infobox drug/formatChemSpider;
UNII	Tɛmplet:Infobox drug/formatUNII; Tɛmplet:Infobox drug/formatUNII;
KEGG	Tɛmplet:Infobox drug/formatKEGG; Tɛmplet:Infobox drug/formatKEGG;
ChEBI	Tɛmplet:Infobox drug/formatChEBI; Tɛmplet:Infobox drug/formatChEBI;
ChEMBL	Tɛmplet:Infobox drug/formatChEMBL; Tɛmplet:Infobox drug/formatChEMBL;
NIAID ChemDB	Tɛmplet:Infobox drug/formatChemDBNIAID; Tɛmplet:Infobox drug/formatChemDBNIAID;
PDB ligand	Tɛmplet:Infobox drug/formatPDBligand; Tɛmplet:Infobox drug/formatPDBligand;
CompTox Dashboard (EPA)	Tɛmplet:Infobox drug/formatCompTox; Tɛmplet:Infobox drug/formatCompTox;
ATC code	Tɛmplet:Infobox drug/formatATC; Tɛmplet:Infobox drug/formatATC;
Chemical and physical data
Formula	Tɛmplet:Infobox drug/chemical formula
Molar mass	Tɛmplet:Chem molar mass
3D model (JSmol)	Tɛmplet:Infobox drug/formatJmol; Tɛmplet:Infobox drug/formatJmol;
	SMILES CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O;
	InChI InChI=1S/C43H66N12O12S2/c1-5-22(4)35-42(66)49-26(12-13-32(45)57)38(62)51-29(17-33(46)58)39(63)53-30(20-69-68-19-25(44)36(60)50-28(40(64)54-35)16-23-8-10-24(56)11-9-23)43(67)55-14-6-7-31(55)41(65)52-27(15-21(2)3)37(61)48-18-34(47)59/h8-11,21-22,25-31,35,56H,5-7,12-20,44H2,1-4H3,(H2,45,57)(H2,46,58)(H2,47,59)(H,48,61)(H,49,66)(H,50,60)(H,51,62)(H,52,65)(H,53,63)(H,54,64)/t22-,25-,26-,27-,28-,29-,30-,31-,35-/m0/s1Tɛmplet:Stdinchicite; Key:XNOPRXBHLZRZKH-DSZYJQQASA-NTɛmplet:Stdinchicite;

Tɛmplet:Infobox drug/maintenance categories

Oxytocin ninsala ni mali, ka di daabiligu yuli booni Pitocin ni ŋa yu' shɛŋa din pahi, nyɛla tila' shɛli bɛ ni yiɣi na peptide oxytocin puuni na.^[2]^[6] Di nyɛla tila' shɛli din tahiri dɔɣim surugu darigibu mini waɣisibu dɔɣim piligu, ni din yɛn che ka dɔɣim niŋ kaliŋkaliŋ, n ti pahi di che ka ʒim ŋmaari yomyom dɔɣim nyaaŋa ^[2] Ŋa tuma zuɣu, bɛ chibiri li mi n-niŋdi muscle ni bee ʒi' sɔya ni ^[2]

oxytocin ninsala ni mali ŋɔ zaŋ ku bukaata nyɛla din ni tooi tahi dɔɣim surugu darigibu mini waɣisibu na n-ti lahi yaɣi ka ŋa ni tooi n dam bia maa daalaafee ^[2] Yɛlimuɣisira shɛŋa din tooi yɔli zaŋ kpa tilaa polo n nye din tooi n-kpuhiri ma ŋun zaŋ li n ku o bukaata dɔɣim saha tiri yaha ka ni tooi che ka o suhi bɛ lahi tɔri yomyom.^[2] Di yɛlimuɣisir'kpɛma shɛŋa n nye dɔɣim surugu tɔhigibu n ti pahi water intoxication di yi ti niŋ ka bɛ chibi li n-niŋ paɣ' puulana maa ni n ti lahi yaɣi ^[2] Allergic reactions kamani anaphylaxis gba nyɛla din ni tooi dɔli tim ŋɔ chibibu ^[2]

Oxytocin sala ningbuŋ ni vihi m-baŋ yuuni daa nyɛla 1906^[7]^[8]Tilaa ŋɔ nyɛla din gba pahi anduniya yaangi zuɣu alaafee yili bɛ ni mi shɛli World Heallth Organization la tilahi din mali anfaani kara la puuni..^[9] Yuuni 2014 pulini, tim ŋɔ daa luɣi shɛŋa ŋan nabi lɛbigi pam daa lula Amɛrika laɣiri $0.10 mini 0.56 sumsuuni n ti chibibu kam.^[10]

Kundivihira

↑ OXYTOCIN injectable - Essential drugs. Archived 28 Silimin gɔli August 2021 at the Wayback Machine
1 2 3 4 5 6 7 8 Oxytocin. The American Society of Health-System Pharmacists.
1 2 WHOCC - ATC/DDD Index. Archived 18 Silimin gɔli August 2020 at the Wayback Machine
↑ (September 2012) "Intranasal oxytocin administration is reflected in human saliva". Psychoneuroendocrinology 37 (9): 1582–86. DOI:10.1016/j.psyneuen.2012.02.014. PMID 22436536.
↑ (2012) "Salivary levels of oxytocin remain elevated for more than two hours after intranasal oxytocin administration". Neuro Endocrinology Letters 33 (1): 21–25. PMID 22467107.
↑ The Oxford Handbook of Prosocial Behavior. Oxford University Press. 2015. p. 354. ISBN 978-0-19-539981-3. Archived from the original on 2017-08-01.
↑ Hurlemann, Rene; Grinevich, Valery (2018). Behavioral Pharmacology of Neuropeptides: Oxytocin (in English). Springer. p. 37. ISBN 978-3319637396. Archived from the original on 2021-08-28. Retrieved 2020-05-25.
↑ (May 1906) "On some physiological actions of ergot". The Journal of Physiology 34 (3): 163–206. DOI:10.1113/jphysiol.1906.sp001148. PMID 16992821.
↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
↑ Oxytocin.

[MSF2020I-1] OXYTOCIN injectable - Essential drugs. Archived 28 Silimin gɔli August 2021 at the Wayback Machine

[AHFS2015-2] 1 2 3 4 5 6 7 8 Oxytocin. The American Society of Health-System Pharmacists.

[WHO2020DDD-3] 1 2 WHOCC - ATC/DDD Index. Archived 18 Silimin gɔli August 2020 at the Wayback Machine

[pmid22436536-4] (September 2012) "Intranasal oxytocin administration is reflected in human saliva". Psychoneuroendocrinology 37 (9): 1582–86. DOI:10.1016/j.psyneuen.2012.02.014. PMID 22436536.

[pmid22467107-5] (2012) "Salivary levels of oxytocin remain elevated for more than two hours after intranasal oxytocin administration". Neuro Endocrinology Letters 33 (1): 21–25. PMID 22467107.

[6] The Oxford Handbook of Prosocial Behavior. Oxford University Press. 2015. p. 354. ISBN 978-0-19-539981-3. Archived from the original on 2017-08-01.

[7] Hurlemann, Rene; Grinevich, Valery (2018). Behavioral Pharmacology of Neuropeptides: Oxytocin (in English). Springer. p. 37. ISBN 978-3319637396. Archived from the original on 2021-08-28. Retrieved 2020-05-25.

[pmid16992821-8] (May 1906) "On some physiological actions of ergot". The Journal of Physiology 34 (3): 163–206. DOI:10.1113/jphysiol.1906.sp001148. PMID 16992821.

[WHO21st-9] World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[10] Oxytocin.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]